sponsored
PatientsVille.com Logo

PatientsVille

Triatec Medical Research Studies

Up-to-date List of Triatec Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Triatec Medical Research Studies

Rank Status Study
1 Recruiting Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
Conditions: Diabetes Type 2;   Diabetic Nephropathy;   Vascular Disease
Interventions: Drug: Ramipril;   Drug: Clopidogrel
Outcome Measures: Changes in Asymmetric dimethylarginine (ADMA) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in High-sensitivity C-reactive protein (HsCRP) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in soluble CD40 Ligand (sCD40L)blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in urine 8-isoprostane-F2 levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Reduction in albumine to creatine ratio after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in ADMA blood levels after treatment with ramipril;   Increase of Glomerular Filtration Rate (GFR) after combined treatment with ramipril and clopidogrel and after ramipril monotherapy;   Change from baseline in carotid intima-media thickness after combined therapy with ramipril and clopidogrel and after ramipril monotherapy
2 Recruiting Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Condition: Metabolic Syndrome
Interventions: Drug: Ramipril;   Drug: HCTZ-hydrochlorothiazide;   Drug: Ramipril+HCTZ
Outcome Measure: Changes in Insulin Sensitivity
3 Recruiting Ramipril for the Treatment of Oligospermia
Conditions: Oligospermia;   Teratospermia;   Asthenozoospermia;   Male Infertility
Interventions: Drug: Ramipril;   Drug: Placebo
Outcome Measures: Sperm density in infertile men with documented oligospermia.;   Total Motile Sperm Count(TMSC), total sperm count, sperm motility, and morphology in the ejaculate.;   Pregnancy rate;   Hormonal profile
4 Recruiting Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome
Condition: Renal Insufficiency, Chronic
Interventions: Drug: Ramipril;   Drug: placebo to ramipril
Outcome Measures: Time to next disease level;   Incidence of Adverse Drug Events before progression;   Albuminuria after three years;   Adverse Drug Events over three years
5 Unknown  Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants
Condition: Intermittent Claudicants
Intervention: Drug: Ramipril
Outcome Measures: The primary outcome measure for this trial is the Maximum Walking Distance (MWD). Treadmill exercise test will be used to estimate the maximum distance the participant can walk at a speed of 2.5 km/h with a 10 degree incline.;   Other clinical indicators of lower limb ischaemia: a) Patient Reported Walking Distance (PRWD) b) Treadmill Intermittent Claudication Distance (ICD) c) Ankle Brachial Pressure Index at rest (ABPI- r) and following treadmill testing (ABPI - t);   Quality of life: a) Generic - measured using the SF36, SF8 and EuroQol (EQ5D) instruments b) Disease specific - measured using the VascuQol;   Cardiovascular prognosis using: a) Framingham, PROCAM, QRISK and Manchester charts scoring systems b) B-type Natriuretic Peptide (BNP) and N- terminal prohormone BNP (NT-proBNP) and a Lipid profile ( LDL, HDL, Total Cholesterol, Triglycerides);   Markers of endothelial function and ischaemia reperfusion a) IL6 b) soluble Intercellular Adhesion Molecule-1 (sICAM -1) c) sE selectin d) Urine Albumin Creatinine Ratio ( UACR);   Arterial effects: a) Arterial stiffness by measuring the Pulse Wave Velocity and assessing the effects on the extracellular matrix by measuring Metalloproteinases (MMPs) and Tissue Inhibitor Metalloproteinases (TIMPs). b) Flow mediated vasodilatation;   Health economics (cost effectiveness / utility)
6 Not yet recruiting Aliskiren Study of Safety and Efficacy in Senior Hypertensives
Condition: Hypertension
Interventions: Drug: Aliskiren;   Drug: Amlodipine;   Drug: Ramipril;   Drug: Hydrochlorothiazide
Outcome Measures: Change from baseline in mean sitting systolic blood pressure (MSSBP) to week 8;   Number of patients with serious adverse events and adverse events;   Number of patients with hyperkalemia, hypotension and reduction of estimated glomerular filtration rate (eGFR);   Change from baseline in mean sitting systolic blood pressure (MSSBP) at the end of double blind period;   Percentage of patients achieving blood pressure control;   Percentage of patients with major cardiovascular events;   Number of patients with gastrointestinal tract cancer
7 Unknown  Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria
Conditions: Hypertension;   Type 2 Diabetes Mellitus;   Microalbuminuria
Interventions: Drug: Ramipril;   Drug: Imidapril
Outcome Measures: Size of the reduction of urinary albumin in 24 hours to the various controls;   1. Size of the reduction of mean 24-hour average daytime and nighttime average. 2. Size of the reduction of central blood pressure. 3. Magnitude of changes in plasma concentrations of angiotensin II, bradykinin and BNP after 24 weeks of treatment.
8 Unknown  Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
Conditions: Left Atrial Volume;   Hypertensive Heart Disease;   Antihypertensive Drugs;   Diastolic Function;   Renin Angiotensin System
Interventions: Drug: ramipril;   Drug: irbesartan
Outcome Measures: left atrial volume;   diastolic function;   systolic and diastolic blood pressure
9 Unknown  Ramipril Versus Carvedilol in Duchenne and Becker Patients
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy
Interventions: Drug: carvedilol;   Drug: ramipril
Outcome Measures: Left ventricular Ejection Fraction, systolic and diastolic left ventricular volumes and LGE (as a quantitative measure) detected by MRI and myocardial Ultrasound Tissue Characterisation data by Echocardiography.;   Prevalence of LGE in DMD and BMD patients,the effects of pharmacological therapy both on LGE evolution and myocardial UTC analysis.
10 Unknown  Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria
Conditions: Hypertension;   Type 2 Diabetes
Interventions: Drug: Ramipril;   Drug: Experimental
Outcome Measures: Antiproteinuric effect as well as antihypertensive effect of aliskiren 300 mg / daily versus ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria.;   Average of 24 hours by ABPM, systolic and diastolic blood pressure;   Average daytime, systolic and diastolic blood pressure;   Average night, systolic and diastolic blood pressure
11 Recruiting Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure
Conditions: Chronic Heart Failure;   Cachexia
Intervention:
Outcome Measures: Pharmacokinetic parameters of bisoprolol and ramipril;   Body composition;   Cachexia diagnosis;   Renal function
12 Unknown  Telmisartan Versus Ramipril After Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Myocardial Infarction;   Coronary Disease
Interventions: Drug: TELMISARTAN;   Drug: RAMIPRIL
Outcome Measures: High sensitivity C-Reactive Protein;   Endothelial Progenitor Cells
13 Not yet recruiting Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD
Condition: Coronary Artery Dissection, Spontaneous
Interventions: Drug: ramipril;   Drug: rosuvastatin;   Drug: placebo
Outcome Measures: Angina frequency domain of the SAQ;   Acute coronary syndrome or hospitalization for angina
14 Recruiting Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
Conditions: Oxidative Stress;   Endothelial Dysfunction
Interventions: Drug: ramipril (ACE inhibitor);   Drug: valsartan (ARB);   Drug: Placebo
Outcome Measures: To compare the long term effects of ACE inhibition or angiotensin receptor blockade versus placebo on biomarkers of fibrinolysis, oxidative stress and inflammation in patients with chronic kidney disease undergoing maintenance hemodialysis;   To compare the long term effects of ACE inhibition or AT1 receptor blockade versus placebo on carotid intima-media thickness (IMT) in patients with chronic kidney disease undergoing maintenance hemodialysis;   Track safety endpoints- hyperkalemia, hypotension, nonfatal myocardial infarction, nonfatal stroke, death from cardiac causes, fatal stroke, death due to any cause.
15 Recruiting Sevelamer in Proteinuric CKD
Condition: Chronic Kidney Disease
Interventions: Drug: Sevelamer;   Drug: Ramipril and Irbesartan
Outcome Measures: 24-h urinary protein excretion;   Office blood pressure;   Glomerular Filtration Rate
16 Unknown  Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
Condition: Metabolic Syndrome X
Interventions: Drug: Eplerenone;   Drug: Ramipril
Outcome Measures: Secreted factors from adipocytes have autocrine, paracrine and endocrine effects that have a deleterious effect on the fibrinolytic system, either by enhancing PAI-1 production or impairing endothelial t-PA release;   This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.
17 Recruiting Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study
Condition: Acute Heart Failure
Interventions: Other: Goal-directed preload and afterload decrement;   Drug: Early goal-directed therapy
Outcome Measures: Death or rehospitalization from HF;   All cause death or rehospitalization
18 Not yet recruiting Cardiac Energetics and Function in Normal Human Ageing
Conditions: Left Ventricular Function Systolic Dysfunction;   Left Ventricular Function Diastolic Dysfunction;   Ageing
Intervention: Drug: Ramipril
Outcome Measures: Vascular Stiffness;   Left Ventricular Energetics;   Left Ventricular Function;   Effects of ACE inhibitor on left ventricular energetics and function in those subjects aged 40 and over
19 Not yet recruiting Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
Condition: Hypertension
Interventions: Drug: Take ACE-I;   Drug: Hold ACE-I
Outcome Measures: Intraoperative Hypotension;   Acute Renal Failure;   Low blood pressure subgroup;   Older age subgroup;   Postoperative Hypertension
20 Not yet recruiting Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure
Conditions: Type 2 Diabetes Mellitus;   Hypertension
Interventions: Drug: Placebo;   Drug: Sitagliptin;   Drug: Aprepitant
Outcome Measures: Blood pressure;   heart rate;   norepinephrine (NE) concentrations;   Low frequency variability of blood pressureactivity, aldosterone;   glucose;   insulin;   DPP4 activity;   ACE

These studies may lead to new treatments and are adding insight into Triatec etiology and treatment.

A major focus of Triatec research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Triatec